TY  - JOUR
AU  - Schmitt-Hoffner, Felix
AU  - van Rijn, Sjoerd
AU  - Toprak, Umut H
AU  - Mauermann, Monika
AU  - Rosemann, Felix
AU  - Heit-Mondrzyk, Anke
AU  - Hübner, Jens-Martin
AU  - Camgöz, Aylin
AU  - Hartlieb, Sabine
AU  - Pfister, Stefan M
AU  - Henrich, Kai-Oliver
AU  - Westermann, Frank
AU  - Kool, Marcel
TI  - FOXR2 Stabilizes MYCN Protein and Identifies Non-MYCN-Amplified Neuroblastoma Patients With Unfavorable Outcome.
JO  - Journal of clinical oncology
VL  - 39
IS  - 29
SN  - 1527-7755
CY  - Alexandria, Va.
PB  - American Society of Clinical Oncology
M1  - DKFZ-2021-01289
SP  - 3217-3228
PY  - 2021
N1  - #EA:B062#LA:B062#/ 2021 Oct 10;39(29):3217-3228
AB  - Clinical outcomes of patients with neuroblastoma range from spontaneous tumor regression to fatality. Hence, understanding the mechanisms that cause tumor progression is crucial for the treatment of patients. In this study, we show that FOXR2 activation identifies a subset of neuroblastoma tumors with unfavorable outcome and we investigate the mechanism how FOXR2 relates to poor outcome in patients.We analyzed three independent transcriptional data sets of in total 1030 primary neuroblastomas with full clinical annotation. We performed immunoprecipitation for FOXR2 and MYCN and silenced FOXR2 expression in two neuroblastoma cell lines to examine the effect on cellular processes, transcriptome, and MYCN protein levels. Tumor samples were analyzed for protein levels of FOXR2 and MYCN.In three combined neuroblastoma data sets, 9
LB  - PUB:(DE-HGF)16
C6  - pmid:34110923
DO  - DOI:10.1200/JCO.20.02540
UR  - https://inrepo02.dkfz.de/record/169155
ER  -